Using physiologically based pharmacokinetic modelling for in silico-in vitro-in vivo extrapolation to predict chemical exposure

被引：0

作者：

Lawless, M. ^{[1
]}

Zhou, H. ^{[1
]}

Fraczkiewicz, G. ^{[1
]}

机构：

[1] Simulat Plus, Lancaster, CA USA

来源：

TOXICOLOGY LETTERS | 2016年 / 258卷

关键词：

D O I：

10.1016/j.toxlet.2016.06.1484

中图分类号：

R99 [毒物学（毒理学）];

学科分类号：

100405 ;

摘要：

P05-016

引用

页码：S119 / S120

页数：2

共 50 条

[1] Physiologically Based Pharmacokinetic (PBPK) Modelling for In Vitro-In Vivo Extrapolation: Emphasis on the Use of Dissolution Data
Ghate, Vivek M.
Chaudhari, Pinal
Lewis, Shaila A.
DISSOLUTION TECHNOLOGIES, 2019, 26 (03): : 18 - 27
[2] Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach
Malmborg, Jonas
Ploeger, Bart A.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2013, 67 (03) : 203 - 213
[3] Analysis of Time-Dependent Pharmacokinetics Using In Vitro-In Vivo Extrapolation and Physiologically Based Pharmacokinetic Modeling
Kim, Min-Chang
Lee, Young-Joo
PHARMACEUTICS, 2022, 14 (12)
[4] PBTK modeling of potential endocrine modulators: In vitro-in vivo extrapolation (IVIVE) and in silico-in vitro based risk assessments
Fabian, E.
Haase, C.
Ramirez, T.
Gomes, C.
Birk, B.
van Ravenzwaay, B.
Landsiedel, R.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2017, 390 : S79 - S79
[5] GENOTYPE-BASED IN VITRO-IN VIVO EXTRAPOLATION (IVIVE) OF EFAVIRENZ PHARMACOKINETICS USING A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL
Xu, C.
Quinney, S.
Guo, Y.
Desta, Z.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S30 - S30
[6] Using in Vitro-In Vivo Extrapolation to Predict Human Clearance
Wang X.
Wang, Xiangling, 1600, Mary Ann Liebert Inc. (41): : 78 - 79
[7] Predictive performance of physiologically based kinetic (PBK) models based on in-silico/in vitro-in vivo extrapolation (IS/IVIVE)
Kalra, P.
Zhou, H.
Lawless, M.
TOXICOLOGY LETTERS, 2023, 384 : S259 - S260
[8] Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure
Karen Rowland Yeo
Jane R. Kenny
Amin Rostami-Hodjegan
European Journal of Clinical Pharmacology, 2013, 69 : 1311 - 1320
[9] Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure
Yeo, Karen Rowland
Kenny, Jane R.
Rostami-Hodjegan, Amin
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (06) : 1311 - 1320
[10] Physiologically based approaches towards the prediction of pharmacokinetics:: in vitro-in vivo extrapolation
De Buck, Stefan S.
Mackie, Claire E.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2007, 3 (06) : 865 - 878

← 1 2 3 4 5 →